Starteck Finance is a non-banking financial company that provides corporate loans, retail financing, and investment services to businesses and individuals in urban and semi-urban India.
The company lacks a durable competitive advantage, as evidenced by an average ROCE of 7.8% which barely covers the cost of capital. While net margins appear high at 33.7%, this is a function of the high-risk corporate lending model rather than pricing power or cost advantages.
Capital is primarily deployed into corporate loans and inter-corporate deposits with related parties. The company frequently seeks enabling resolutions to raise massive amounts of capital (up to ₹1,500 Crores) relative to its small current equity base, suggesting a focus on size over per-share returns.
Five years out, the aggressive corporate lending model collapsed as the high-risk loan book, concentrated in a few entities, soured during a credit tightening cycle. The massive capital raises previously authorized resulted in catastrophic dilution for minority shareholders, while the capital itself was funneled into related-party inter-corporate deposits that proved unrecoverable. The thin spread between the 7.8% ROCE and the rising cost of debt evaporated, leaving the company as a hollow shell of related-party receivables with no underlying cash flow to service its own 1.33 debt-to-equity load.
RichFakir rates Starteck Finance Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Starteck Finance Ltd is trading about 18% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Starteck Finance Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Starteck Finance Ltd's fair value is about ₹206 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →